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Significant but lesser changes in losartan utilization were seen in 
Austria and Belgium. There was no change in losartan utilization 
patterns in Scotland or Spain. Losartan typically generic at low prices, 
leading to appreciable increases in prescribing efficiency in NHS Bury, 
Sweden, Austria, and Belgium. There were some savings in Scotland 
with generic losartan.
Conclusion: Multiple demand-side measures appreciably enhanced 
ARB prescribing efficiency. This mirrors previous findings that mul-
tiple measures are need to change prescribing habits. No significant 
increase in losartan utilization following generics where countries 
have not instigated specific measures suggests authorities cannot rely 
on a “spillover” effect between classes to change physician prescrib-
ing habits. This is the case even with multiple demand-side activities 
encouraging preferential prescribing of generics in related classes. 
This may be exacerbated on this occasion by a more complex mes-
sage; for example, away from ACEIs first line versus ARBs to ACEIs 
+ low cost ARBs first line.
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Introduction: The availability of generic venlafaxine is an opportu-
nity for health authorities to save resources given the prevalence of 
depression. However, depression can be complex to treat, with physi-
cians reluctant to change prescriptions if patients are responding to a 
particular antidepressant. Consequently, there is a need to assess: (1) 
changes in the utilization pattern of venlafaxine versus other newer 
antidepressants before and after the availability of generic venla-
faxine and before and after prescribing restrictions were introduced 
for duloxetine in Sweden limiting prescribing to refractory patients; 
(2) utilization of generic versus originator venlafaxine; and (3) price 
reductions for generic venlafaxine and subsequent expenditure on 
newer antidepressants over time, to guide future reforms.
Patients (or Materials) and Methods: Interrupted time series ana-
lyzing the changes in aggregated dispensed prescriptions (DDDs 
[defined daily doses]) of patients dispensed at least 1 of the newer 
antidepressant from January 2007 to August 2011. This included 
time before the availability of generic venlafaxine to 19 months after 
the availability of generic venlafaxine but before prescribing restric-
tions introduced for duloxetine and to 13 months after prescribing 
restrictions were introduced for duloxetine. Expenditure measured, 
which included price reductions for generic venlafaxine over time.
Results: There was no appreciable change in the utilization of venla-
faxine after generic availability but before prescribing restrictions for 
duloxetine with no appreciable demand-side activities by the regions 
(counties) to preferentially encourage its prescribing. However, the 
utilization of venlafaxine significantly increased after the introduction 
of prescribing restrictions for duloxetine, although no appreciable 
change in the utilization of duloxetine. Principally, generic venlafax-
ine was prescribed and dispensed versus the originator once available. 
There was an appreciable fall in expenditure for venlafaxine follow-
ing generics that lead to a fall in expenditure for newer antidepres-
sants in Sweden after generic venlafaxine became available.
Conclusion: No apparent concerns with generic venlafaxine among 
physicians versus the originator. Multiple demand-side measures 
are needed to change physician prescribing habits. Authorities can-
not rely on a “spillover” effect between classes to change physician 
prescribing habits. The limited influence of prescribing restrictions 
on the subsequent utilization of duloxetine reflects the complexity 
of the disease area versus treating acid-related stomach disorders, 
hypercholesterolemia, or hypertension. However, the influence of the 
prescribing restrictions for duloxetine resulting in increased utiliza-
tion of venlafaxine is encouraging.
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Introduction: White blood cell (WBC) monitoring is mandatory in 
several countries among schizophrenic patients treated by clozap-
ine, because of the risk of drug-induced agranulocytosis. Our aim is 
to compare the cost-effectiveness of 4 WBC- monitoring strategies 
(United Kingdom, United States, Switzerland, and an weekly short-
run monitoring) to the absence of monitoring.
Patients (or Materials) and Methods: We built a semi-Markovian 
model to conduct a cost-utility analysis from a health care perspective 
with a 3-year time horizon, assuming a probability of agranulocytosis 
of 0.7% at 3 years. Clinical and resources used parameters were 
based on national clozapine patients’ registries, cohorts, and Swiss 
pharmacovigilance data; health-related quality of life and mortality 
estimates were derived from literature reviews. Model uncertainty 
was was assessed with 1-way and probabilistic sensitivity analyses.
Results: In our model, compared with the absence of monitoring, all 
4 monitoring strategies increased the quality-adjusted survival simi-
larly by < 1 day, with 5000 patients to monitor to avoid 1 death. The 
incremental cost-effectiveness ratio (ICER) was at least $1,000,000 
per QALY gained for all 4 strategies compared with no monitoring. 
It was higher in strategies with higher frequency and longer moni-
toring duration. The results remain robust in the 1-way sensibility 
analyses and the probabilistic sensitivity analysis, indicating that the 
absence of monitoring strategy had the highest probability of cost-
effectiveness for willingness-to-pay under $1,000,000.
Conclusion: Current WBC monitoring based on current national 
detection guidelines do not appear to be cost-effective. New guide-
lines are needed to improve WBC monitoring in schizophrenic 
patients receiving clozapine.
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